| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lambert-Eaton Myasthenic Syndrome | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Autoimmune Diseases | |||||
| Autoimmune Diseases of the Nervous System | |||||
| Disease | |||||
| Immune System Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Nervous System Diseases | |||||
| Nervous System Neoplasms | |||||
| Neurodegenerative Diseases | |||||
| Neuromuscular Diseases | |||||
| Neuromuscular Junction Diseases | |||||
| Paraneoplastic Syndromes | |||||
| Paraneoplastic Syndromes, Nervous System | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| 3,4-diaminopyridine | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| 4-Aminopyridine | |||||
| 6 | More general drug interventions related to this trial | ||||
| Cardiovascular Agents | |||||
| Membrane Transport Modulators | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Potassium Channel Blockers | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| FDA Office of Orphan Products Development | |||||
| Duke University | |||||
|
